Skip to main content
Equibles

Christine Klaskin

MiNK Therapeutics, Inc. (INKT)
Agenus Inc (AGEN)

Equibles does not estimate personal net worth.

Get an email with a short summary when MiNK Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get INKT alerts

About Christine Klaskin

The proxy statement of Agenus Inc reports total compensation of $332,019 for Christine Klaskin in fiscal 2025, including a base salary of $298,224. Disclosed compensation is on record for 6 fiscal years. Christine Klaskin has spoken on 4 earnings calls across 2 companies, most recently for Agenus Inc on May 12, 2025. Those appearances were for Agenus Inc (AGEN) and MiNK Therapeutics, Inc. (INKT). Agenus Inc is classified in the Biotechnology industry within the Healthcare sector. MiNK Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Agenus Inc includes Garo H. Armen (CEO), Dr. Garo Armen (CFO), Jennifer Buell (COO) and 7 others.

Christine Klaskin on recent calls

“We ended the first quarter 2025 with a consolidated cash balance of $18.5 million compared to $40.4 million at year end 2024. Cash used in operations for the first quarter ended March 31, 2025 with $25.6 million, which is reduced from $38.2 million for the same period in 2024.”
Other, Agenus Inc Q1 FY2025 Earnings Call ·
“We ended the year 2024 with a consolidated cash balance of $40.4 million. This compares to a balance of $76.1 million at December 31, 2023. Cash used in operations for the year ended December 31, 2024 was $158 million.”
Other, Agenus Inc Q4 FY2024 Earnings Call ·
“We ended our third quarter 2022 with a cash, cash equivalents and short-term investment balance of $218.2 million, compared to $238.3 million and $306.9 million on June 30, 2022, and December 31, 2021, respectively.”
CFO, Agenus Inc Q3 FY2022 Earnings Call ·
“We ended the third quarter 2022 with a cash balance of $24.2 million as compared to $38.9 million at December 31, 2021. Cash used in operations for the 9 months and third quarter ended September 30, 2022, was $14.4 million and $5.6 million, respectively.”
CFO, MiNK Therapeutics, Inc. Q3 FY2022 Earnings Call ·

Affiliation history

Company network

Leadership on record at Agenus Inc

Leadership on record at MiNK Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Agenus Inc (AGEN) $298,224 $332,019
2025 MiNK Therapeutics, Inc. (INKT) $29,822 $29,822
2024 Agenus Inc (AGEN) $298,224 $483,477
2024 MiNK Therapeutics, Inc. (INKT) $29,822 $29,822
2023 Agenus Inc (AGEN) $296,239 $712,747
2023 MiNK Therapeutics, Inc. (INKT) $29,624 $29,624
2022 Agenus Inc (AGEN) $287,178 $628,125
2022 MiNK Therapeutics, Inc. (INKT) $27,244 $27,244
2021 Agenus Inc (AGEN) $275,725 $574,832
2021 MiNK Therapeutics, Inc. (INKT) $20,019 $20,019
2020 Agenus Inc (AGEN) $285,166 $507,705

Recent activity